Skip to main content

Advertisement

Table 1 Patient Disposition (Safety Population)

From: The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis

  Cariprazine 1.5–3 mg/d n = 170 Cariprazine 4.5–6 mg/d n = 361 Cariprazine 9 mg/d n = 148 Cariprazine Overall N = 679
Completed, n (%) 70 (41.2) 154 (42.7) 48 (32.4) 272 (40.1)
Reasons for discontinuation, n (%)
 Adverse event 28 (16.5) 29 (8.0) 26 (17.6) 83 (12.2)
 Insufficient therapeutic response 1 (0.6) 11 (3.0) 13 (8.8) 25 (3.7)
 Protocol violation 13 (7.6) 31 (8.6) 10 (6.8) 54 (8.0)
 Withdrawal of consent 44 (25.9) 88 (24.4) 38 (25.7) 170 (25.0)
 Lost to follow-up 11 (6.5) 29 (8.0) 10 (6.8) 50 (7.4)
 Other reasons 3 (1.8) 19 (5.3) 3 (2.0) 25 (3.7)
Entered safety follow-up, (n)% 121 (71.2) 234 (64.8) 102 (68.9) 457 (67.3)